Myriad sues Ambry over cancer gene screening tests
Biotech company Myriad Genetics has filed a patent infringement case against Ambry Genetic Corp for allegedly infringing 10 patents related to genetic diagnostic testing.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
8 August 2013 Ambry Genetics, the laboratory sued last month by biotech company Myriad over patents covering the BRCA1 and BRCA2 genes, has hit back with antitrust claims.